Scientific Program Committee

Wednesday
February 6 Sessions
Session 37 CROI 2008
k Wednesday, 10-11:45 am; Ballroom A
CME
Session 37–Oral Abstracts
Epidemiology of HIV Infection and Scale-up of ART
in Developing Countries
Moderators:
Kevin De Cock, World Hlth Org, Geneva, Switzerland
Dorothy Mbori-Ngacha, Global AIDS Prgm, CDC Kenya, Nairobi
10:00 123 Determinants for HIV Acquisition among Adults in
Uganda: A Population-based, Nationally Representative
Study
Wolfgang Hladik* 1 , J Musinguzi2 , A Opio2 , W Kirungi2 , J Ekwaru1 ,
F Kaharuza1 , R Downing1 , R Bunnell1 , and J Mermin1 1 2 CDC Uganda, Entebbe and AIDS Control Prgm, Ministry of Hlth,
Kampala, Uganda
10:15 124 Measuring the Force of the HIV Epidemic in a Rural
Area of South Africa: The Africa Centre
Till Barnighausen* 1,2 , ML Newell1,3 , F Tanser1 , C Mbizana1 ,
C Wallrauch1 , G Cooke1,4 , Z Gqwede1 , and K Herbst1 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal,
Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA,
US; 3Inst of Child Hlth, Univ Coll London, UK; and 4Imperial Coll,
London, UK
10:30 125 Utility of Routine Viral Load, CD4 Cell Count, and
Clinical Monitoring among HIV-infected Adults in
Uganda: A Randomized Trial
Alex Coutinho* 1 , J Mermin2,3 , J Ekwaru2 , W Were2 , R Bunnell2,3 ,
F Kaharuza2 , L Alexander2 , P Solberg2 , J Tappero2 , and D Moore2,4 1 2 TASO and Infectious Disease Inst, Kampala, Uganda; CDC
Uganda, Entebbe; 3CDC Kenya, Nairobi; and 4Univ of British
Columbia, Vancouver, Canada
10:45 126 Long-term CD4 Response to Potent ART among ARTnaïve
Patients in Several Low-income Countries
Denis Nash* 1 , M Katyal1 , M Brinkhof2 , S Tuboi3 , P Braitstein4 ,
E Balestre5 , M May6 , E Sprinz7 , N Kumarasamy8 , M Egger2 , and
the Antiretroviral Therapy in Low Income Countries (ART-LINC)
Collaboration of IEDEA
1Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US;
2 3 4 Univ of Berne, Switzerland; Univ of Pittsburgh, PA, US; Indiana
Univ Sch of Med, Indianapolis, US; 5Univ Victor Segalen, Bordeaux,
France; 6Univ of Bristol, UK; 7Federal Univ of Rio Grande do Sul,
Porte Alegre, Brazil; and 8YRGCARE, Chennai, India
11:00 127 Evaluation of Clinical and Immunologic Outcomes from
the National ART Program in Rwanda, 2004 to 2005
Francois Ndamage* 1 , D Lowrance1,2,3 , A Rukundo1 , E Kayirangwa4 ,
F Ndagije2 , D Hoover5 , J Hanson6 , W Lo7 , A Ayaba4 , and T Ellerbrock3 1Treatment and Res on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda;
2Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms,
Kigali, Rwanda; 3Global AIDS Prgm, CDC, Atlanta, GA, US;
4 5 Global AIDS Prgm, CDC Rwanda, Kigali; Rutgers Univ, New
Brunswick, NJ, US; 6Global AIDS Prgm, CDC Namibia, Windhoek;
and 7Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms,
New York, NY, US
11:15 128 Early Detection of Effect on Adult Mortality of a
Government ART Program in Rural KwaZulu Natal,
South Africa
Till Barnighausen* 1,2 , G Cooke1,3 , K Herbst1 , A Kany Kany1 , and
ML Newell1,4 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal,
Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA,
US; 3Imperial Coll, London, UK; and 4Univ Coll London, UK
11:30 129LB High HIV Prevalence among Males in Discordant
Partnerships in a Full Access Door–Door VCT
Program in Rural Uganda
E Tumwesigye* 1 , S Asiimwe1 , E Muganzi1 , M Achom2 , D Kabatesi2 ,
and J Tappero2 1 2 Integrated Community Based Initiatives and CDC Uganda
20 15th Conference on Retroviruses and Opportunistic Infections
k Wednesday, 10-11:45 am; Ballroom B/C
CME
Session 38–Oral Abstracts and Scientific Overview
Drug Delivery, Interactions and Genetic Variability
Moderators:
Giovanni Di Perri, Univ of Turin, Italy
Courtney Fletcher, Univ of Nebraska Med Ctr, Omaha, US
10:00 131 Low Tenofovir Concentrations in Cerebrospinal Fluid
Brookie Best* 1 , S Letendre 1 , P Koopmans 2 , D Clifford 3 , A Collier 4 ,
B Gelman 5 , J McArthur 6 , D Simpson 7 , E Capparelli 1 , R Ellis 1 , and the
CHARTER Group
1 Univ of California, San Diego, US; 2 Radboud Univ Nijmegen Med
Ctr, The Netherlands; 3 Washington Univ, St Louis, MO, US; 4 Univ
of Washington, Seattle, US; 5 Univ of Texas Med Branch, Galveston,
US; 6 Johns Hopkins Univ, Baltimore, MD, US; and 7 Mt Sinai Sch of
Med, New York, NY, US
10:15 132 Drug Interaction between Antimalarial Drugs and
Lopinavir/Ritonavir
Polina German* 1 , S Parikh 2 , J Lawrence 2 , N Lindegardh 3 ,
P Rosenthal 2 , D Havlir 2 , E Charlebois 2 , G Dorsey 2 , and F Aweeka 1
1 Univ of California, San Francisco, Sch of Pharmacy, US; 2 San
Francisco Gen Hosp, Univ of California, US; and 3 Faculty of
Tropical Med, Mahidol Univ, Bangkok, Thailand
10:30 133 Genetic Variation in Accessory Metabolic Pathways
Is Associated with Extreme Efavirenz Exposure in
Individuals with Impaired CYP2B6 Function
Julia di Iulio* 1 , M Rotger1 , R Lubomirov1 , L Decosterd1 , CB Eap2 ,
and A Telenti1 1 2 Univ Hosp Ctr, Univ of Lausanne, Switzerland and Cery Hosp,
Lausanne, Switzerland
10:45 134 Long-acting TMC278, a Parenteral Depot Formulation
Delivering Therapeutic NNRTI Concentrations in
Preclinical and Clinical Settings
Gerben van ‘t Klooster* 1 , R Verloes1 , L Baert1 , F van Velsen1 ,
MP Bouche2 , K Spittaels1 , J Leempoels3 , P Williams1 , G Kraus1 , and
P Wigerinck1 1 2 Tibotec BVBA, Mechelen, Belgium; Johnson & Johnson Pharma
R&D, Beerse, Belgium; and 3Johnson & Johnson Pharma R&D,
Merksem, Belgium
11:00 135LB Maraviroc Pharmacokinetics in Blood Plasma, Genital
Tract Fluid and Tissue in Healthy Female Volunteers
J Dumond1 , Kristine Patterson* 1 , A Pecha1 , R Werner1 , E Andrews2 ,
B Damle2 , R Tressler2 , J Worsley3 , K Boggess1 , and A Kashuba1 1 2 Univ of North Carolina at Chapel Hill, US; Pfizer Inc, New York,
NY, US; and 3Pfizer Global R&D, Sandwich, Kent, UK
11:15 136
The Evolution of Therapeutic Drug Monitoring in
ART
Giovanni Di Perri* and S Bonora
Univ of Turin, Italy